Result of AGM

Results of Annual General Meeting

Oxford and Newcastle, UK, 11 June 2015- e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.

- Ends -

e-Therapeutics plc

Malcolm Young, CEO / Steve Medlicott, Finance Director

Tel: +44 (0) 1993 883125

www.etherapeutics.co.uk 

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

www.n1singer.com 

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics is a drug discovery and development company with a proprietary platform in network pharmacology, an innovative approach to drug discovery based on advances in network science and chemical biology. e-Therapeutics' platform is generating more potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery.The Company's discovery and development activity addresses age-related diseases, including cancer and central nervous system disorders, and it is fully funded to advance its programme into 2019, including phase II clinical data and multiple regulatory submissions.

e-Therapeutics has a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103. It has a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The company has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, potent telomerase inhibition in anti-cancer; ETS3100, potent small molecule anti-TNFα; ETS2400, potent Hedgehog pathway inhibition; and ETS6200, in neuroprotection.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.